CA2590939C - Aminopyrimidine compounds and methods of use - Google Patents

Aminopyrimidine compounds and methods of use Download PDF

Info

Publication number
CA2590939C
CA2590939C CA2590939A CA2590939A CA2590939C CA 2590939 C CA2590939 C CA 2590939C CA 2590939 A CA2590939 A CA 2590939A CA 2590939 A CA2590939 A CA 2590939A CA 2590939 C CA2590939 C CA 2590939C
Authority
CA
Canada
Prior art keywords
ethyl
pyrimidin
ylamino
dione
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2590939A
Other languages
English (en)
French (fr)
Other versions
CA2590939A1 (en
Inventor
Adrian Leonard Smith
Paul Edward Brennan
Frenel Fils Demorin
Gang Liu
Nick A. Paras
Daniel Martin Retz
Elizabeth Rainbeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA2590939A1 publication Critical patent/CA2590939A1/en
Application granted granted Critical
Publication of CA2590939C publication Critical patent/CA2590939C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2590939A 2004-12-17 2005-12-16 Aminopyrimidine compounds and methods of use Expired - Lifetime CA2590939C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63660404P 2004-12-17 2004-12-17
US60/636,604 2004-12-17
PCT/US2005/045863 WO2006066172A1 (en) 2004-12-17 2005-12-16 Aminopyrimidine compounds and methods of use

Publications (2)

Publication Number Publication Date
CA2590939A1 CA2590939A1 (en) 2006-06-22
CA2590939C true CA2590939C (en) 2011-10-18

Family

ID=36588221

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2590939A Expired - Lifetime CA2590939C (en) 2004-12-17 2005-12-16 Aminopyrimidine compounds and methods of use

Country Status (9)

Country Link
US (2) US7786132B2 (cg-RX-API-DMAC10.html)
EP (1) EP1831207B1 (cg-RX-API-DMAC10.html)
JP (1) JP4932735B2 (cg-RX-API-DMAC10.html)
CN (1) CN101115749B (cg-RX-API-DMAC10.html)
AU (1) AU2005316312B2 (cg-RX-API-DMAC10.html)
CA (1) CA2590939C (cg-RX-API-DMAC10.html)
ES (1) ES2397362T3 (cg-RX-API-DMAC10.html)
MX (1) MX2007007032A (cg-RX-API-DMAC10.html)
WO (1) WO2006066172A1 (cg-RX-API-DMAC10.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
DE102005048072A1 (de) * 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
TW200800201A (en) * 2005-11-18 2008-01-01 Lilly Co Eli Pyrimidinyl benzothiophene compounds
CA2634442A1 (en) * 2005-12-22 2007-07-05 Icagen, Inc. Calcium channel antagonists
EP2474546A1 (en) 2006-01-23 2012-07-11 Vertex Pharmaceuticals Inc. Thiophene-carboxamides useful as inhibitors of protein kinases
EP2007757B1 (en) 2006-04-13 2012-10-03 Vertex Pharmceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
CA2652816A1 (en) 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
JP2009538305A (ja) 2006-05-23 2009-11-05 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド
CN100422331C (zh) * 2006-06-28 2008-10-01 南京农业大学 一个簇毛麦丝氨酸/苏氨酸激酶基因及其所编码的蛋白质
BRPI0713187A2 (pt) * 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
US8101628B2 (en) 2006-12-21 2012-01-24 Eli Lilly And Company Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
SI2125794T1 (sl) * 2006-12-21 2011-02-28 Lilly Co Eli Spojine imidazolidinonil aminopirimidina za zdravljenje raka
EP2128156A4 (en) * 2007-01-29 2011-05-18 Santen Pharmaceutical Co Ltd NEW OXADIAZOL DERIVATIVES AND THIADIAZONE DERIVATIVES WITH THE NEOVASCULARIZATION HEMMENDER EFFECT
WO2008144222A2 (en) * 2007-05-16 2008-11-27 Eli Lilly And Company Triazolyl aminopyrimidine compounds
EA016781B1 (ru) * 2007-05-16 2012-07-30 Эли Лилли Энд Компани Триазолиламинопиримидиновые соединения
BRPI0818804A2 (pt) * 2007-11-01 2015-04-22 Actelion Pharmaceuticals Ltd Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
CA2730844A1 (en) * 2008-07-17 2010-01-21 Thomas Bretschneider Heterocyclic compounds used as pesticides
WO2010068863A2 (en) 2008-12-12 2010-06-17 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
CN102439091A (zh) * 2009-02-06 2012-05-02 国立大学法人北海道大学 荧光溶剂化变色色素
US20120263646A1 (en) * 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
JP2013147428A (ja) * 2010-04-27 2013-08-01 Dainippon Sumitomo Pharma Co Ltd 新規２−ヘテロアリール単環ピリミジン誘導体
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
AU2013216935C1 (en) 2012-02-08 2017-12-14 John Emmerson Campbell Heteroaryl compounds and methods of use thereof
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
CN104860900A (zh) * 2014-02-25 2015-08-26 中国药科大学 噻唑类化合物、其制备方法及其在制药中的用途
CN105884711A (zh) * 2014-12-16 2016-08-24 中国药科大学 噻唑类化合物、其制备方法及其在制药中的用途
DK3319939T3 (da) * 2015-07-08 2025-02-24 Cv6 Therapeutics Ni Ltd Hydantoin indeholdende deoxyuridintriphosphatase-inhibitorer
WO2017013237A1 (en) 2015-07-23 2017-01-26 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
MX2020012771A (es) 2015-12-17 2022-10-04 Arqule Inc Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-ami na sustituida.
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN112125879A (zh) * 2020-09-29 2020-12-25 浙江永太科技股份有限公司 一种卡格列净中间体2-(4-氟苯基)噻吩的制备方法
CN114133337A (zh) * 2020-12-14 2022-03-04 成都泰蓉生物科技有限公司 一种2-取代的赖氨酸的制备方法
CA3211349A1 (en) * 2021-03-09 2022-09-15 Basf Se Tricyclic pesticidal compounds
EP4479042A1 (en) 2022-02-18 2024-12-25 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer
CN117050051B (zh) * 2023-08-14 2026-05-26 上海药坦药物研究开发有限公司 一种2-溴-1-(5-碘噻吩-2-基)-乙酮的纯化方法
WO2026025073A1 (en) * 2024-07-26 2026-01-29 Taugen, Llc Compounds and uses to treat tauopathy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG47583A1 (en) 1986-01-13 1998-04-17 American Cyanamid Co 4,5,6-Substituted-n- (substituted-phenyl) -2- pyrimidinamines
DE4025891A1 (de) 1990-08-16 1992-02-20 Bayer Ag Pyrimidyl-substituierte acrylsaeureester
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
CZ20012350A3 (cs) 1998-12-24 2001-09-12 Aventis Pharmaceuticals Products Inc. Substituované (aminoiminomethyl nebo aminomethyl) benzoheteroarylové sloučeniny
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
GB2361236B (en) 2000-03-29 2002-04-24 Cyclacel Ltd Pyrimidines useful against proliferative disorders
WO2002020495A2 (en) 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3
MXPA03010961A (es) 2001-05-31 2004-02-27 Vertex Pharma Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
CA2460909A1 (en) * 2001-09-28 2003-04-10 Cyclacel Limited N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds
RS95404A (sr) * 2002-05-03 2006-10-27 Schering Aktiengesellschaft Tiazolidinoni i njihova primena kao inhibitora polo like kinaze
US7361665B2 (en) * 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
MXPA05001544A (es) 2002-08-08 2005-04-19 Smithkline Beecham Corp Compuestos de tiofeno.
WO2004043936A1 (ja) 2002-11-14 2004-05-27 Kyowa Hakko Kogyo Co., Ltd. Ｐｌｋ阻害剤
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina

Also Published As

Publication number Publication date
EP1831207A4 (en) 2010-09-15
MX2007007032A (es) 2007-07-04
CN101115749A (zh) 2008-01-30
EP1831207B1 (en) 2012-11-14
US20070185133A1 (en) 2007-08-09
US20100010014A1 (en) 2010-01-14
ES2397362T3 (es) 2013-03-06
WO2006066172A1 (en) 2006-06-22
AU2005316312B2 (en) 2009-10-22
US7858785B2 (en) 2010-12-28
EP1831207A1 (en) 2007-09-12
JP2008524248A (ja) 2008-07-10
AU2005316312A1 (en) 2006-06-22
CA2590939A1 (en) 2006-06-22
US7786132B2 (en) 2010-08-31
JP4932735B2 (ja) 2012-05-16
CN101115749B (zh) 2011-06-22

Similar Documents

Publication Publication Date Title
US7786132B2 (en) Aminopyrimidine compounds and methods of use
RU2277911C2 (ru) Модуляторы аденозиновых рецепторов
US6498165B1 (en) Src kinase inhibitor compounds
EP1633740B1 (en) 5-(acylamino)indazole derivatives as kinase inhibitors
CN102781942B (zh) 用作食欲肽受体调节剂的二取代八氢吡咯并[3,4-c]吡咯
KR101332975B1 (ko) 오로라 키나제 조절제 및 사용 방법
JP2013536193A (ja) ヘテロアリール類およびその使用
WO2010038081A2 (en) Heterocyclic derivatives and methods of use thereof
WO2009049028A1 (en) Pyrrolopyrimidine compounds and their use as janus kinase modulators
AU2005286795A1 (en) Chemical compounds
AU2005228899A1 (en) Substituted thiophene derivatives as anti-cancer agents
AU2009271019A1 (en) Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
JP2015147804A (ja) Ｐｉ３ｋ阻害剤としてのヘテロアリールおよびその使用
KR20120089648A (ko) 결핵 억제제로서의 피리미딘 화합물
JP2008524248A5 (cg-RX-API-DMAC10.html)
EP1758578B1 (en) Novel indazole carboxamides and their use
AU2008254318B2 (en) Triazolyl aminopyrimidine compounds
JP2009539770A (ja) Ｐｌｋに対する活性を有するベンゾイミダゾール置換チオフェン誘導体
AU2007334039B2 (en) Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206